Alternatively Spliced Exon B of Myosin Va Is Essential for Binding the Tail-Associated Light Chain Shared by Dynein†

Zsuzsa Hódi,‡ Attila L. Németh,‡ László Radnai,‡ Csaba Hetényi,‡ Katalin Schlett,§ Andrea Bodor,|| Andráss Perczel,‡ and László Nyitray*,‡

Departments of Biochemistry, Physiology and Neurobiology, Theoretical Chemistry, and Organic Chemistry,  Eötvös Loránd University, Budapest, Hungary

Received May 18, 2006; Revised Manuscript Received July 31, 2006

ABSTRACT: A 10 kDa dynein light chain (DLC), previously identified as a tail light chain of myosin Va, may function as a cargo-binding and/or regulatory subunit of both myosin and dynein. Here, we identify and characterize the binding site of DLC on myosin Va. Fragments of the human myosin Va tail and the DLC2 isoform were expressed, and their complex formation was analyzed by pull-down assays, gel filtration, and spectroscopic methods. DLC2 was found to bind as a homodimer to a ~15 residue segment (Ile1280–Ile1294) localized between the medial and distal coiled-coil domains of the tail. The binding region contains the three residues coded by the alternatively spliced exon B (Asp1284–Lys1286). Removal of exon B eliminates DLC2 binding. Co-localization experiments in a transfected mammalian cell line confirm our finding that exon B is essential for DLC2 binding. Using circular dichroism, we demonstrate that binding of DLC2 to a ~85 residue disordered domain (Pro1235–Arg1320) induces some helical structure and stabilizes both flanking coiled-coil domains (melting temperature increases by ~7 °C). This result shows that DLC2 promotes the assembly of the coiled-coil domains of myosin Va. Nuclear magnetic resonance spectroscopy and docking simulations show that a 15 residue peptide (Ile1280–Ile1294) binds to the surface grooves on DLC2 similarly to other known binding partners of DLCs. When our data are taken together, they suggest that exon B and its associated DLC2 have a significant effect on the structure of parts of the coiled-coil tail domains and such a way could influence the regulation and cargo-binding function of myosin Va.

Class V myosins are involved in the short-range intracellular transport of vesicles and molecules mostly in the actin-rich cortical region of the cell (for a review, see ref 1). They are processive actin-based motors moving by a “hand-over-hand” mechanism along actin filaments (2, 3). Mammalian genomes contain three myosin V heavy-chain genes: MYO5A, MYO5B, and MYO5C. Mutations of MYO5A are responsible for the dilute phenotype and Griscelli syndrome type 1 in mice and humans, respectively (4, 5). Myosin Va (myoVa) is composed of two heavy chains, six calmodulins (one or two could be substituted by essential light chains) associated with the neck region, and a 10 kDa light chain, originally identified as a light chain of dynein (called DLC; alternative names are LC8, DLC8, and PIN) bound to the tail region (6, 7). The tail region contains coiled-coil dimerizing domains interrupted with noncoiled-coil regions and a C-terminal globular tail domain (GTD) involved in cargo binding (8, 9). At least six isoforms of myoVa are expressed, partially tissue specifically, by alternative splicing of three exons (exons B, D, and F) in the tail region. An isoform that is expressed abundantly in the brain includes only exon B, while a mainly melanocyte-specific isoform includes exons D and F (10–12). Exon F together with GTD was found to bind to melanosomes via the adaptor protein melanophilin (13–15). An isoform containing only exon D associates with vesicles near the Golgi area (16). No function for exon B has been assigned thus far. The regulation of the ATPase and the motor activity of myoVa are thought to be achieved by Ca2+ binding to the calmodulin (CaM) subunits and folding back the globular tail domain toward the heads (17–21).

DLC was first described as a light-chain component of the Chloramydomonas outer dynein arm and later a component of mammalian flagellar and cytoplasmic dyneins (22, 23). In the multisubunit cargo-binding tail region of the dynein motor, it is associated with the intermediate chain (24). DLC is a highly conserved protein, with >90% sequence identity between any two orthologues (7, 25). Mammalian species contain two DLC genes (DYNLL1 and DYNLL2; the proteins referred to here as DLC1 and DLC2). DLCs were found to bind to a diverse array of proteins and even to RNAs
besides the two motor proteins, such as the neuronal nitric oxide synthase (nNOS) enzyme (26, 27), IkBa (28), bicoid mRNA via the swallow protein (29, 30), PTH mRNA (31), GKAP and gephrin postsynaptic scaffolding proteins (32–34), Bim and Bmf “BH3-only” proapoptotic proteins (35, 36), p53-binding protein 1 (37), several virus proteins (38, 39) and possibly many other proteins (40, 41). Mutations of DLC cause apoptotic cell death in Drosophila (42). On the basis of the above properties, it was hypothesized that DLCs function as a cargo adapter of myoVa and dynein motors in intracellular transport and/or sequestration; moreover, as soluble proteins, they have additional function(s) in eukaryotic cells (26, 34, 43). Recent results suggest that DLC can also function as a tumor promoter by supporting cell survival through p21-activated kinase-dependent phosphorylation (44). Reports originally showed that DLC1 and DLC2 bound equally to both motors and that both isoforms were identified as light chains of isolated cytoplasmic dynein complexes (25, 34). However, recent studies indicated that in vivo DLC1 and DLC2 bind to dynein and myoVa, respectively (35, 36). Crystal and NMR structures of DLC1 were determined both in the apo form and in complex with short binding peptides of nNOS and Bim, respectively (43, 45). The solution structure of DLC2 is also known (35). DLC forms a homodimer with 2-fold symmetry. A five-stranded β sheet and two α helices are arranged in a novel fold. Four strands of the β sheet from each monomer and the fifth strand from the other monomer form the core, while the two pairs of α helices cover the outer faces of the dimer. Two deep hydrophobic target binding grooves are formed at the two edges of the β sheet; the target peptides were found to bind as antiparallel β strands extending the central β sheets.

Here, we report that the three residues of the alternatively spliced exon B of the myoVa tail is part of the binding site of DLC2 within a disordered domain between the medial and distal coiled-coil regions of the tail. Importantly, binding of DLC2 induces some folding of its binding domain and stabilizes the flanking coiled-coil domains, promoting the assembly of the two heavy chains. Molecular docking and nuclear magnetic resonance (NMR) spectroscopic studies indicate that the myoVa-binding peptide occupies the same surface groove as other known binding partners of DLC2. Binding of the DLC2 dimer to the dimeric heavy chain is likely asymmetric, allowing for a third partner, a cargo, or regulatory protein to interact with the motor complex. Preliminary results of this work have been reported (46).

**MATERIALS AND METHODS**

**Expression and Purification of DLC2 and myoVa Fragments.** Human DLC2 (Uniprot accession number Q96FJ2) was obtained from human brain cDNA by the RevertoAid First cDNA synthesis kit (Fermentas). A human pancreas cDNA library (Stratagene) was used as a template in polymerase chain reaction (PCR) reactions to generate several myoVa constructs (numbering as in Q9Y4I1-2): MV-(1244–1442), MV2(1158–1368), M1(1244–1386), M11-(1244–1368), M11AB(1244–1368, Δ1284–1286), M2-(1307–1442), M3(1244–1316), M4(1244–1284), M6(1275–1316), M7(1275–1297), M7ΔB(1275–1297, Δ1284–1286), and M8(1294–1316). The myosin isoforms thus obtained have an exon pattern in the alternatively spliced tail region: ABCEG (10). One isoform containing exon D (ACDEG) was cloned independently from human Jurkat cell cDNA: M1AB+D(1244–1395) (numbering as in Q9Y4I1-1). The PCR products were cloned into pGEX4T-1 (Amersham) and/or pET15b (Novagen) vectors using BamHI/Ndel and EcoRI. Constructs were transformed in BL21(DE3)pLysS or BL21(DE3) “Rosetta” (Novagen) cells. After induction, cells were grown at 37 °C for 3 h in 2YT medium (except for NMR spectroscopy in minimal media containing 15NH4Cl). Glutathione-S-transferase (GST)-fusion and His-tagged proteins were purified on glutathione Sepharose (Amersham) and Ni2+-affinity columns (Novagen), respectively. The His-tagged proteins were digested by thrombin and further purified on HiTrapQ ion-exchange column chromatography (Amersham). The protein concentration was determined using UV spectroscopy, by measuring the absorbance at 280 nm using calculated molar extinction coefficients (47) or by a modified Lowry method (48).

**Peptide Synthesis.** The DLC2-binding peptide of myoVa (IQPKDDKKNTMTDSTI) was synthesized in-house by standard solid-phase techniques using Fmoc chemistry. The DLC-binding nNOS peptide (EMKDGTIQVDRL) was a kind gift of Dr. Rodriguez-Crespo.

**Analytical Gel-Filtration Chromatography.** MyoVa constructs, DLC2, and their complexes were analyzed by gel-filtration chromatography using Superdex 200 HR 10/30 and 75 HR 10/30 columns (Amersham) in 150 mM NaCl, 20 mM Tris, and 0.5 mM dithiothreitol (DTT) at pH 7.6 and 4 °C with a 0.5 mL/min flow rate. Absorbances were detected at 220 and 280 nm by a LKB VWM2141 photometer (Pharmacia). Apparent molecular mass of the proteins were estimated using low-molecular-weight standards (Amersham).

**GST Pull-Down Assay.** For direct binding experiments, the soluble phases of Escherichia coli cell lysates containing GST–myosin fragments were incubated first with DLC2 and then with glutathione-Sepharose beads for 30 min in phosphate-buffered saline (PBS) buffer containing 2 mM 2-mercaptoethanol (β-ME) at 25 °C. The pellets were washed twice with the same buffer and eluted with reduced glutathione. For direct competitive binding experiments, the GST–M7–DLC2 complex-bound beads were mixed with a DLC2-binding peptide of nNOS successively at 1:1, 10:1, and 100:1 molar ratios in PBS. The remaining DLC2 was eluted from the beads and resolved along with other samples on 15% tricine sodium dodecyl sulfate–polyacylamide gel electrophoresis (SDS–PAGE) as in ref 49.

**Native Gel Electrophoresis.** Complex formation between myoVa constructs and DLC2 was studied by native PAGE prepared similarly to SDS–PAGE but without SDS. A constant concentration of a myoVa construct (7–12 μM) was incubated for 30 min with an increasing amount of DLC2 (molar ratio from 1:0.125 to 1:4) in 150 mM NaCl, 20 mM Tris, and 2 mM β-ME at pH 7.6. Samples were run on 12–15% PAGE on ice. Band intensities were quantitated after Coomassie Brilliant Blue staining with Genetools software (Sunnyvale). Binding stoichiometry was estimated from plotting peak areas of the complex against the ratio of the two proteins. Because it was only the complex that migrated as a sharp band, the apparent dissociation constant was determined by fitting a plot of the fraction saturation versus the total DLC2 concentration.
**Transfection and Co-localization.** NE-4C, a mouse neuroectodermal stem cell line (50) was used for transfection assays. Cells were cultivated in minimum essential medium (Sigma) supplemented with 4 mM glutamine, 5% fetal calf serum (Merck), and 40 μg/mL gentamycin (Sigma). For transient transfections, 7.5×10^4 cells were seeded onto poly-L-lysine (Sigma) coated 13 mm diameter glass coverslips in 24 well plates. The next day after seeding, cells were transfected with plasmid constructs using Lipofectamine 2000 reagent (Invitrogen). The constructs used for the transfection assays were as follows: human DLC2 and myoVa tail fragments (from residues Ala1244 to the C-terminal Val, either containing the tail exon B or not; exons D and F were absent in these constructs) were cloned into both pEGFP-C1 and pDsRed2-N1 vectors (Clontech) in frame with the respective fluorescence proteins. A total of 1 μg of plasmid was used for single transfection experiments, while in cotransfection assays, 0.5 μg of green-fluorescent protein (GFP)-tagged DLC2 was combined with 1.5 μg of DsRed-tagged myosin constructs (or vice versa). In all cases, 2 μL of Lipofectamine 2000 was used for each microgram of plasmid per well. Growth medium was replaced 6 h after the transfection, and cells were grown for an additional 18 h and then fixated by 4% paraformaldehyde in PBS at pH 7.4 for 20 min at room temperature. Nuclei were labeled by DRAQ5 for 10 min (1/2000 dilution; BioStatus Ltd.), and then coverslips were washed and mounted using Mowiol 4.88 (Polysciences). Confocal microscopy was carried out using an Olympus IX71 microscope equipped with a 60× oil immersion objective, 488 nm argon, 546 and 633 nm helium–neon lasers, and FluoView500 software. A sequential scanning mode was used during recordings to completely rule out potential cross-talk between channels.

**Structure Predictions.** COILS and PAIRCOIL were used to predict coiled-coil regions in the myoVa tail. PONDR (51) and GlobProt (52) were applied to search for unstructured regions. Secondary-structure predictions were performed by the PHD server (53).

**Limited Proteolysis.** Limited proteolysis of the myoVa constructs M1, MV2, M3 (20–60 μM), myoVa fragment–DLC2 complexes (1:2 molar ratio), and DLC2 alone were performed at either 0 or 20 °C with trypsin (1:100 weight ratio to the myosin fragment) and protease K at 25 °C (1:400 weight ratio) in 150 mM NaCl, 20 mM Tris-HCl, and 2 mM β-ME at pH 7.6. The proteolyzed fragments were blotted to a nitrocellulose membrane and analyzed by N-terminal peptide sequencing.

**Circular Dichroism (CD) Spectroscopy.** CD spectra were recorded on a JASCO J720 spectropolarimeter equipped with a Neslab RTE-111 temperature controller using a 1 mm cuvette and wavelength range between 190 and 250 nm. The DLC2 spectra were subtracted from that of the myoVa fragment–DLC2 complexes. All measurements were performed in 20 mM phosphate buffer at pH 7.6 containing 150 mM NaCl and 0.5 mM DTT at 15–30 μM protein concentrations. For thermal denaturation experiments, protein samples were heated at a constant 1 °C/min rate and the CD signal was monitored at 220 nm. Curves were analyzed for a two-state transition between the folded dimer (D) and unfolded monomers (M). Dissociation/unfolding constant, \( K_d = [M]^2/[D] \), is defined by

\[
K_d = 2C_{tot}f_M^2/(1/f_M) 
\]

\( C_{tot} \) is the total protein concentration, and \( f_M \) is the fraction of the monomeric chain. The measured ellipticity per residue depends upon \( f_M \) according to

\[
\theta_{obs} = f_M(\theta_M - \theta_D) + \theta_D 
\]

\( \theta_M \) and \( \theta_D \) are ellipticity per residue of the monomer and dimer, respectively. \( \theta_D \) was assumed to depend linearly upon the temperature and was calculated from \( \theta_D = \theta_D + \alpha T \), where \( \theta_D \) is the hypothetical ellipticity at 0 K and \( \alpha \) is a constant. \( K_d \) is a function of the temperature and total protein concentration

\[
K_d = C_{tot}\exp[(\Delta H/RT) - 1/2]/R 
\]

\( \Delta H \) is the van’t Hoff enthalpy of unfolding at the transition midpoint temperature \( T_m \). Where \( f_M = 0.5 \), and \( R \) is the gas constant. The difference in heat capacity between the unfolded monomers and the native dimers is assumed to be small and could be neglected (54). Equations 1–3 were applied for nonlinear curve fitting. After \( \Delta G \) and \( \Delta S \) were determined from \( \Delta G = -RT \ln K \) and \( \Delta G = \Delta H - \Delta S \), the melting temperature \( (T_m) \) at \( \Delta G = 0 \) \((K_d = 1)\) was calculated (54). Concentration dependence studies were carried out by monitoring the molar ellipticities at 222 nm (using cuvettes with light paths from 1 mm to 1 cm). Curves were fitted assuming a two-state monomer–dimer transition. Data for trifluoroethanol (TFE) experiments were acquired after 5 min of incubation of the samples with 50 vol% vol TFE. To estimate secondary-structure elements, deconvolution of the spectra was performed using CDSSTR at the Dichroweb server (55). Helical content was also estimated as described in ref 56.

**NMR Spectroscopy.** All measurements were performed on a Bruker DRX500 spectrometer equipped with a z-gradient 5 mm triple-resonance probe head at 300 and 310 K. Temperature values were checked with the 1,2-ethanediol calibration method. Chemical shifts were referenced to an external sodium 4,4-dimethyl-4-silapentane-1-sulphonate (DSS) standard. \(^{1}H,^{15}N\) heteronuclear single-quantum coherence (HSQC) spectra of \(^{15}N\)-labeled DLC2 in free form and complexed to a synthetic myoVa peptide representing the DLC binding sequence (IQPKDDKNMTDSTI) were acquired by the fastHSQC pulse program using the WATERGATE sequence for water suppression. Sequential backbone resonance assignments for the unbound DLC2 were obtained from the 3D HNCA, HN(CO)CA, and C(CO)NH correlation measurements performed on the double-labeled \(^{15}N,^{13}C\) DLC2 sample, partly by a comparison with data obtained by Day et al. (55). Spectra were processed by XWIN-NMR (Bruker AG) and NMRPipe (57) software packages and analyzed by XEASY. The \(^{15}N\)-labeled DLC2 and the myoVa-binding peptide were dissolved in 20 mM NaCl, 0.04% Naazide, 20 mM sodium phosphate buffer at pH 7.6, 2 mM tris(2-carboxyethyl)phosphine (TCEP), and a 9:1 H2O/D2O ratio. The protein concentration was kept at ~1.0 mM. Stepwise titration with the myoVa peptide (concentration of the stock solution was 18 mM) was performed up to a 1:1.25 protein/ligand ratio. The complex was subsequently titrated with adding a DLC-binding nNOS peptide (EMKDT-
Identification of the DLC2 Binding Site on the myoVa Tail by in Vitro Pull-Down Assay and Size-Exclusion Chromatography. The tail region of class V myosins can be divided into three predicted coiled-coil domains interrupted by noncoiled-coil segments and followed by the cargo-binding globular tail domain (62). In our nomenclature, as schematically illustrated in Figure 1, the proximal coiled-coil domain (residues Arg903–His1104) starts just after the calmodulin-binding neck domains and ends at the calpain-sensitive PEST site (residues Val1105–Lys1159). The medial (Leu1150–Asp1234) and distal (Leu1132–Val11419) coiled-coil domains are separated by a ~85 residue noncoiled-coil region (residues Pro1235–Arg1320). Note that part of this region (Arg1248–Val1263) shows a low probability (~0.5) of coiled-coil formation, and a secondary-structure prediction reveals peptide stretches with high α-helical propensity. The coiled-coil prediction breaks down for a short stretch of peptide in both the medial (around Pro1195) and distal (around Pro1365) coiled-coil domains. Prediction programs were applied to see if the noncoiled-coil segment is able to form a globular domain or rather represent an intrinsically unstructured domain of the myoVa tail. PONDR (51) predicted that the whole region except for the last couple of residues is more likely unfolded than folded. On the other hand, GlobProt (52) using different definitions predicted that it is only a short stretch of peptide (Pro1282–Met1289) that may not fold into any stable secondary structure.

Previous yeast two-hybrid experiments showed that DLC2 binds between residues 1236–1420 of the tail region of brain-specific myoVa (34). The identified myoVa isoform has an alternatively spliced exon pattern of ABCG (10, 11). We have produced overlapping truncated recombinant myoVa tail fragments (Figure 1) and used analytical gel filtration and GST pull-down assays to further narrow the DLC2 binding site on the heavy chain. Construct MV corresponds to the yeast two-hybrid clone. A longer fragment (MV2) was also designed to check the effect of a N-terminal extension to the binding region (also comprising a coiled-coil segment) on the DLC2–myoVa interaction. Construct M1AB+D contains exon D but not exon B. Because recent results had shown that the DLC2 isoform binds to myoVa in vivo (35, 36), we used this paralogue throughout this work.

Analytical gel filtration was employed to show interactions between DLC2 and the myoVa tail fragments. DLC2 formed complexes with the MV and M1 fragments but not with the M2 fragment (data not shown). GST pull-down assays (Figure 2) show that DLC2 binds robustly to GST–M3, GST–M6, and GST–M7. M7 consists of 23 residues with amino acid sequence SQKEAIQPDKDNTMTDSTILLE. Because this peptide contains the alternatively spliced exon B (underlined), we have made two constructs without exon B (M7ΔB and M11ΔB). DLC2 binding of GST–M7ΔB was tested by the pull-down assay (Figure 2), while that of M11ΔB was checked by analytical gel filtration and compared to M11 (Figure 3). The fragments lacking exon B did not show any interaction with DLC2, thus strongly suggesting...
that exon B is part of the DLC2 binding site and is essential for binding. Human DLC2 runs as a dimer (apparent molecular mass of 21 kDa) by size-exclusion chromatography under the conditions used (see the globular molecular-weight markers in Figure 3B), and dissociation to monomers could be observed only at pH 4 in accordance with previous results (63). Densitometric analysis of the bands on SDS-PAGE of DLC2-MV and DLC2-M11 complexes (compared to known amounts of the individual components) shows a stoichiometry of 1:1; i.e., one DLC2 dimer binds to one myoVa heavy-chain dimer (inset of Figure 3A). It is noteworthy that the elution volume of the myoVa tail constructs compared to globular marker proteins has a considerably higher apparent molecular weight than globular proteins of similar sizes. The construct M1ΔB+D did not pull-down DLC2, indicating that isoforms containing exon D instead of exon B do not bind the tail light chain (data not shown). When the above results were summarized, progressive truncation led to the narrowing of the DLC2 binding region to a ∼15 residue continuous peptide segment of the myoVa heavy chain between residues Ile1280 and Ile1294.

Binding of DLC2 to the myoVa tail fragments was confirmed by native gel electrophoresis (Figure 4A). Titration of M11 with DLC2 shows saturation at 1:1 stoichiometry, providing further evidence that one DLC2 dimer binds to one myoVa heavy-chain dimer (Figure 4B), corroborating the densitometric analysis of DLC2 on tissue-purified myoVa (6). Fitting densitometric data to a single binding site equation results in a dissociation constant of ~0.4 μM. Higher complexes did not appear even in the presence of high excess DLC2, suggesting that one DLC2 dimer likely bridges the two heavy chains. The same results were obtained with MV2, M3, a monomeric myoVa tail construct, also showed saturation binding to DLC2 with the expected stoichiometry of two M13 monomers bound to one DLC dimer.

**DLC2 Binding to Exon B of myoVa in Vivo as Revealed by Confocal Microscopy.** The interactions between GFP-tagged DLC2 and DsRed-tagged myoVa fragments with and without exon B were tested in NE-4C cells, a mouse neuroectodermal stem cell line (50). For these experiments, we used a myoVa tail construct containing the globular tail domain. In single transfections, GFP-tagged DLC2 was found evenly distributed in transfected cells, while both DsRed-tagged myoVa constructs formed patches (possibly aggregates) in the cytoplasm (data not shown). Cotransfection of GFP—DLC2 together with DsRed—myoVa lacking exon B led to similar expression patterns: GFP—DLC2 remained evenly distributed within the cell, even in those places where its expression overlapped with large patches of DsRed—myosin (Figure 5). A strikingly different GFP—DLC2 distribution was observed when cells were cotransfected with exon B containing DsRed—myoVa: GFP—DLC2 formed
patches that highly co-localized with DsRed–myoVa patches in the cytoplasm (Figure 5). Exon B containing DsRed–myoVa was less prone to make large patches (aggregates) when it was cotransfected with GFP–DLC2, indicating the stabilization of the dimer tail region in the presence of DLC2. When the transfection experiments with mammalian cells were taken together, they corroborated our in vitro finding that DLC2 could interact with the myoVa tail only if exon B was expressed.

**DLC2 Globally Protects the Tail Domains against Limited Proteolysis.** The structural effect of DLC2 binding to myoVa fragments was studied by limited tryptic and proteinase K digestion (Figure 6). DLC2 is highly stable against limited proteolysis at the enzyme/substrate ratio used for the experiment. M1 alone (18 kDa) was degraded into smaller fragments, while a ~16 kDa fragment was clearly protected in the presence of 2-fold molar excess DLC2. The protected fragment has the same N-terminal sequence as M1, indicating that residues were cleaved off the C-terminal region (likely at residue Arg1396). Thus, DLC2 protected tryptic cleavage sites near and remote from its binding site, suggesting a global stabilizing effect on the myosin tail. The constructs M11 and M11B were designed on the basis of the limited proteolysis results, and they did not contain the proteolytically sensitive C-terminal residues of M1. In the case of MV2, both coiled-coils were partially protected in the presence of DLC2 and a shorter stable fragment was produced with the N terminus at Gly1198, suggesting that the stabilizing effect of DLC2 applies to both flanking coiled-coil domains. The identified cleavage sites within the medial and distal coiled-coil domains, respectively, are located at the coiled-coil breaks (see above). The broad specificity proteinase K gave qualitatively similar results. It degraded MV2 to many fragments but at significantly slower rates in the presence of DLC2. The fragments that were protected by DLC2 binding (~14.5, ~16.5, and ~19.5 kD) were analyzed by N-terminal sequencing. On the basis of the sequences and the size of the peptides, the DLC2-protected sites were identified at or near Ala1199 (next to a site that was also protected from tryptic digestion), Val1274, and Leu1326. We conclude that DLC2 stabilizes myoVa fragments and globally protects the tail domains around its binding site from proteolytic digestion.

**CD Spectroscopy Shows That DLC2 Binding Stabilizes Its Binding Domain and the Flanking Coiled-Coil Domains.** The effect of DLC2 binding on the secondary structure of myoVa fragments was monitored by CD spectroscopy (Figure 7). The far-UV CD spectrum of human DLC2 is similar to that reported previously for *Drosophila* DLC (63), typical of an $\alpha/\beta$ protein (Figure 7A). The spectrum of a representative of the myoVa fragments (MV2) is shown in Figure 6A and is typical for an $\alpha$-helical coiled-coil protein with double minima at 208 and 222 nm and a ratio of $\theta_{222}/\theta_{208}$ close to 1 (64). Calculated helical contents of M11, M2, and MV2 at room temperature are ~20%, ~45%, and ~42%, respectively. The spectra of the DLC2-bound myoVa fragments...
were generated by subtracting the DLC2 spectrum from that of the complex. A 10% increase in $\alpha$-helix in the case of M11 but no change in the similarly obtained spectrum of M11ΔB was observed. The increase in the calculated helical content of M11 could correspond to ~13 residues folded into the $\alpha$-helix upon DLC2 binding, assuming that there is no change in the secondary structure of DLC2 upon complex formation. The latter assumption is based on the fact that the apo- and peptide-bound DLC structures are superimposable (45). In the case of the MV2–DLC2 complex, $\alpha$-helix content increased by 4% (Figure 7A), indicating that ~10 residues gained $\alpha$-helical structure. The spectrum of MV2 was also recorded in the presence of 50% TFE, a substance known to promote $\alpha$-helix formation in peptide chains with high helix propensity (65). The molar ellipticity increased at 222 nm, and the $\theta_{222}/\theta_{208}$ ratio shifted well below 1, indicating uncoiling of MV2 into single $\alpha$ helices (Figure 7A).

The stability of the myoVa fragments and their DLC2 complexes was investigated by thermal denaturation, monitoring the ellipticity change at 222 nm. Spectral changes were accompanied by a decrease in the $\theta_{222}/\theta_{208}$ ratio and an isodichroic point at 203 nm, consistent with a two-state transition of the myoVa fragments. A 10% increase in the helix content of M11 could correspond to the presence of exon B changes GFP–myoVa and DsRed–myoVa (red) signals appears yellow in the merged picture. Nuclei were labeled by DRAQ5 (blue). Bars represent 10 $\mu$m.

Figure 6: Limited proteolysis of myoVa fragments. (A) Limited trypic digestion of M1 (10 $\mu$M) preincubated with DLC (1:1.5 molar ratio) and (B) M1 alone were performed in 150 mM NaCl, 20 mM Tris, and 2 mM $\beta$-ME at pH 7.6 and 0 °C with a 1:100 weight ratio of enzyme/myoVa fragment. Samples in the lines represent the proteolytic fragments after 5–60 min of digestion and 0 min as a control. (C) Proteinase K digests of MV2 in the presence and absence of DLC performed at 25 °C with a 1:400 weight ratio of enzyme/myoVa fragment. Lanes show the proteolytic fragments after 0–60 min with (+) and without (−) DLC. DLC is stable against digestion with both proteases under the conditions used. Arrows points to DLC2-protected fragments, which are analyzed by N-terminal sequencing.
dimer without DLC2 ($K_d = 29 \mu M$), which is stabilized ~15 times in the presence of DLC2 ($K_d = 2 \mu M$). M11 weakly dimerizes at 25 °C even in complex with DLC2 ($K_d = 5.5 \mu M$). Table 1 also shows that the presence of DLC2 increased the concentration-independent melting temperatures ($T_m$) of both M11 and MV2 by ~7 °C. The dissociation constant of MV2 was also determined at 30 °C protein concentration as in A. (C) Thermal unfolding profiles of M11 ($\Delta$), the M11–DLC2 complex ($\nabla$), MV2 ($\blacktriangle$), and the MV2–DLC2 complex ($\blacklozenge$) as functions of the monomer fraction ($f_M$). Solid lines represent nonlinear curve fitting for a two-state transition using eqs 1–3 (see the Materials and Methods). Observed melting temperatures are 20.9, 28.2, 36, and 41.1 °C for M11, the M11–DLC2 complex, MV2, and the MV2–DLC2 complex, respectively. The inset of C shows the concentration dependence of MV2 as followed by molar ellipticity changes at 222 nm and 37 °C. The solid line is fitted to a two-state transition with a calculated dissociation constant of 17 μM. For clarity, not all data points are illustrated. (D) Thermal unfolding profiles of M11AB ($\blacktriangle$), the complex of M11AB and DLC2 ($\nabla$), MV2 ($\blacktriangle$), the complex of MV2 and DLC2 (○), and DLC2 alone (●). Protein samples (16 μM) were heated at a constant 1 °C/min rate, and ellipticity was monitored at 222 nm.

FIGURE 7: CD spectroscopy of myoVa constructs and their complexes with DLC2. (A) Far-UV spectra of DLC2 (△), MV2 (●), the complex of MV2 and DLC2 after the subtraction of the DLC2 spectrum (○), and MV2 in the presence of 50% TFE (■) were recorded at 16 μM monomer concentration in 20 mM phosphate buffer at pH 7.6 containing 150 mM NaCl and 0.5 mM DTT at 25 °C. (B) Far-UV spectra of M3 (●), the complex of M3 and DLC2 after the subtraction of the DLC2 spectrum (○), and M3 in the presence of 50% TFE (■) were recorded at 30 μM protein concentration as in A. (C) Thermal unfolding profiles of M11 (△), the M11–DLC2 complex (○), MV2 (■), and the MV2–DLC2 complex (○) as functions of the monomer fraction ($f_M$). Solid lines represent nonlinear curve fitting for a two-state transition using eqs 1–3 (see the Materials and Methods). Observed melting temperatures are 20.9, 28.2, 36, and 41.1 °C for M11, the M11–DLC2 complex, MV2, and the MV2–DLC2 complex, respectively. The inset of C shows the concentration dependence of MV2 as followed by molar ellipticity changes at 222 nm and 37 °C. The solid line is fitted to a two-state transition with a calculated dissociation constant of 17 μM. For clarity, not all data points are illustrated. (D) Thermal unfolding profiles of M11AB (○), the complex of M11AB and DLC2 (△), MV2 (■), the complex of MV2 and DLC2 (○), and DLC2 alone (●). Protein samples (16 μM) were heated at a constant 1 °C/min rate, and ellipticity was monitored at 222 nm.
whether the myoVa binding site on DLC2 is the same as that for the other binding partners, we performed a peptide competition experiment. The GST–M7–DLC2 complex-bound glutathione Sepharose beads were titrated with increasing amounts of a DLC-binding nNOS peptide (EMKDTGIQVDRL). The peptide was able to disrupt the interaction of GST–M7 with DLC2 in a dose-dependent manner (Figure 8A). The fact that the nNOS peptide was able to compete with the myoVa fragment manifests that they share the same binding site on the surface of DLC2.

The titration of 15N-labeled DLC2 with a 15 residue nonlabeled myoVa peptide (IQPKDDKNTMTDSTI) was also monitored by 2D 1H–15N HSQC NMR measurements (Figure 8B). The HSQC spectrum of human DLC2 clearly resembles the one obtained by Day et al. (35). Already, at low peptide concentrations, two sets of peaks appeared, with one set belonging to the apo DLC2 and the other belonging to the complexed form. As the amount of the peptide increased, the intensity of the free enzyme peak for the corresponding amino acid residue decreased, while the peak belonging to the bound residue increased in intensity. This is in accordance with a slow exchange between the two forms on the NMR time scale. Careful integration of a few selected resonances corresponding to the side chains of the myoVa peptide and the DLC binding crevice. Side-chain interactions of exon B residues could strongly contribute to the binding affinity of myoVa to DLC; Asp1284 and Asp1285 are hydrogen-bonded to the binding groove of the ligand Bim peptide MSDKKSTQT known from NMR structure determination (see the Materials and Methods for details). Docking of a 10 residue myoVa peptide (Ac-PKDDKNTMTDSTI) resulted in a complex where the peptide is bound firmly to the target binding surface groove of DLC2 (Figure 9). When the docking energies of the above myoVa-binding peptide were compared with another peptide lacking exon B (Ac-PKDDKNTMTDSTI), their relative binding strengths to DLC2 were estimated. The Ac-PKDDKNTMTDSTI-NMe peptide has a significantly higher affinity to DLC2 (~12.5–25 kJ/mol) than the Ac-PKDDKNTMTDSTI-NMe peptide. Interestingly, while the Bim peptide forms eight hydrogen bonds and one salt bridge with DLC2, the backbone of the Ac-PKDDKNTMTDSTI-NMe peptide is involved in only four hydrogen bonds. The Bim peptide binds to the target-accepting groove of DLC2 as an antiparallel β strand extending the mixed β sheet that forms the dimer interface. In the docked structure, the myoVa peptide does not form a β strand along its entire length; only a short antiparallel β structure is apparent comprising exon B and the loop connecting the 3rd and 4th strands of the DLC2 monomer. The rest of the peptide sits at the bottom of the groove making several hydrophobic interactions. There are numerous interactions present between the side chains of the myoVa peptide and the DLC binding crevice. Side-chain interactions of exon B residues could strongly contribute to the binding affinity of myoVa to DLC; Asp1284 and Asp1285 are hydrogen-bonded to Thr70 and Tyr65, respectively, and Lys1286 forms a salt bridge with Asp12 in the docked structure.

**DISCUSSION**

**Exon B of the MyoVa Tail Is an Essential Part of the DLC Binding Site.** In this study, we have narrowed the binding site in human myoVa by direct solution binding assays to a ~15 residue segment (Ile1280–Ile1294) localized within a noncoiled-coil domain flanked by predicted coiled-coil domains. Because this domain (Pro1235–Arg1320) binds DLC2, we henceforth call it the DLC2 binding domain (DBD). The binding region contains three residues, coded by the alternatively spliced exon B (AspAspLys). Removal of exon B eliminates DLC binding, also affirmed by cotransfection experiments.

The tail region of myoVa is alternatively spliced at three exons. Exons B, D, and F are combinatorically included or excluded from the expressed heavy chain, providing at least six isoforms that could have specific functions (16). Our results establish a function for the 3 residue long exon B, forming an essential part of the binding site for the
tail-associated DLC in the mainly brain-specific splice form of myoVa. Although exon D closely follows the identified DLC binding sequence, it is not involved in the binding. The major role of the alternative tail exon-coded sequences of myoVa appears to provide specific binding surfaces to different interacting partners (16). Interestingly, the other two mammalian myosin V paralogue genes, MYO5B and MYO5C, do not contain exon B; thus, their protein products lack the tail-associated light chain. Sequence analysis of all of the known myoVa genes points to the appearance of these three residue insertions in the vertebrate lineage (results are available from the authors by request). A comparison of the
known vertebrate exon B sequences shows that the third residue is invariably Lys, while the first and second residues must be negatively charged and could be either Asp or Glu.

During the course of the present study, Lajoix et al. (67) has reported the identification of a DLC1 binding site on chicken myoVa using a immobilized peptide-scanning technique; the shortest peptide found to bind to DLC1 was EDKNTMTD. Surprisingly, the same method in another laboratory failed to identify a DLC binding site (68). The molecular structure of the DLC1–Bim complex (PDB 1F95). The molecular surface of DLC2 is shown. Putative binding site residues on DLC2 are highlighted: green, identified by both docking and a chemical shift of amide resonances in 1H-15N HSQC spectra of the complex (Figure 8); blue, identified by docking only; and yellow, identified by NMR only. The position of exon B residues (AspAspLys) is indicated. (A) Target peptide binding groove is shown from above (A) and rotated 90° (B). Only one of the binding peptides is shown on the homodimeric DLC2. The figure was made by YASARA and rendered by POV-Ray.

**FIGURE 9:** Docking of a myoVa peptide to DLC2. The myoVa binding peptide Ac-PKDDKNTMTD-NMe (red sticks) was docked using AutoDock 3.0 after energy minimization of the average NMR structure of the DLC1–Bim complex (PDB 1F95). The molecular surface of DLC2 is shown. Putative binding site residues on DLC2 are highlighted: green, identified by both docking and a chemical shift of amide resonances in 1H-15N HSQC spectra of the complex (Figure 8); blue, identified by docking only; and yellow, identified by NMR only. The position of exon B residues (AspAspLys) is indicated. (A) Target peptide binding groove is shown from above (A) and rotated 90° (B). Only one of the binding peptides is shown on the homodimeric DLC2. The figure was made by YASARA and rendered by POV-Ray.

DLC Acts as a “Molecular Glue” To Stabilize the Medial and Distal Coiled-Coil Domains of MyoVa. Spectroscopy measurements indicated that the recombinant monomeric DBD does not fold into a stable three-dimensional structure but forms an intrinsically unfolded domain (68) that acquires some helical structure in the presence of bound DLC2. However, we cannot rule that DBD is partially stabilized in its natural sequence environment by the neighboring coiled-coil domains. More strikingly, binding of DLC2 is able to stabilize not only its immediate binding domain but also the flanking coiled-coil domains. Without DLC, the medial and distal coiled-coil segments are only marginally stable at physiologically relevant temperature (37 °C, ~20 μM). Sequence analysis of the medial and distal coiled-coils could, at least, partially explain their low stability. For their length (about five continuous heptade repeats at each end of DBD), they contain many destabilizing polar residues at the core “a” and “d” positions (9 of 21). Such a weak coiled-coil segment has recently been described in the crystal structure of a conventional myosin tail (69). It is conceivable that the heavy chains of myoVa tails without the bound DLC2 do not form dimers beyond the PEST site. Assuming that the intracellular protein concentration is 150–200 mg/mL (70) and that myoVa represents about 1% of the total protein, its average concentration is in the range of a few micromolar. On the basis of these numbers, one can estimate that only ~5% of MV2 forms dimers at 37 °C. The full-length myosin is likely dimeric under these conditions, but the heavy chains in the distal tail could be separated, affecting the function of the motor protein. Binding of DLC2 to the tail stabilizes both the medial and distal coiled-coils against at least order of magnitude differences in $K_d$ values at physiological temperatures. An increase in molar ellipticities at 222 nm accompanied by an increase in the ratio of ellipticities at 222 and 208 nm indicates an increase in higher ordered helical structures (i.e., coiled-coil) and suggests that DLC2 acts remotely by stabilizing the flanking coiled-coil domains. In light of these results, one can wonder about the mechanism of such an allosteric effect of DLC2 binding. A plausible explanation might be that one DLC2 dimer is able to cross-link two DBDs and thus, by physically bringing closer the two heavy chains, stabilizes the attached coiled-coils. Interestingly, the only detailed interaction study between DLC1 and two target proteins, dynein intermediate chain and the *Drosophila* swallow protein (30, 71), suggested a similar stabilizing role of DLC1. It binds to a partially disordered region of the dynein intermediate chain, which gains structure only upon DLC1 binding (71), and it promotes the assembly of the coiled-coil domain of the swallow protein flanking the DLC1 binding site (30). These findings correspond exactly to the features deduced in this work from studying the formation of the DLC2–myoVa complex. Our results strengthen the conclusion of Barbar et al. (30, 71) that DLC could promote the assembly of protein complexes as a “molecular glue” by increasing the ordered structure of its interacting partners.

**Structural/Functional Implication of the DLC2–MyoVa Interaction.** It is clear from our peptide competition and NMR spectroscopic and docking studies that myoVa is able to bind to the same surface groove of DLC2 as other known binding partners. The crystal structure of a 13 residue peptide fragment from nNOS bound to DLC1 showed that the peptide binding site is a deep hydrophobic cleft formed by strands β3, β4, and β5 from one protomer and α2 from the other. The peptide interacts extensively, via backbone hydrogen bonds and side-chain hydrophobic and hydrophilic interactions, with strand β3 in an antiparallel manner, extending the central β sheet of DLC1 to six antiparallel β strands (43, 45). The same binding characteristics were obtained by NMR spectroscopy of Bim and Bmf binding to DLC1 and DLC2, respectively (35, 45). On the basis of the
residues implicated in binding by NMR and docking studies, even if sharing a common binding groove, myoVa may behave somewhat differently. The docking model shows that the myoVa peptide does not form a continuous β strand but only a short one involving the three exon B residues. A more detailed comparison of the known structures is precluded by the relatively large rmsd of the docking model, owing to the large number of atoms involved in the simulation. How is the DLC binding sequence of myoVa related to other DLC binding sites? Previously, biochemical and mutational analysis of many DLC partners identified two consensus sequences (K/R)XTQT and G(I/V)QV(D/E) (41). When all known DLC binding sequences were compared, Lajoix et al. (67) found DKGTQT being the most frequent binding motif among diverse sequences. The promiscuous nature of the partner binding site of DLCs is thought to be based on the conformational breathing of its binding groove (45, 67). Substitution analysis indicated that the Gln, flanked by two hydrophobic residues, is the most critical residue for determining the binding strength of many DLC partners. The only DLC binding sequence where this Gln is substituted by Met is myoVa. This Gln caps α helix 2, while the flanking residues are bound to β strands 2 and 3 in the hydrophobic groove. Missing interactions with Gln could contribute to the weaker affinity of the myoVa peptide to DLC2 compared to other binding peptides. The replacement of the corresponding Met to Gln in the synthetic binding peptide indeed resulted in strongly increased binding (67). $K_D$ of the myoVa peptide to DLC2 was found to be $\sim 30 \mu M$; however, binding of the longer myoVa constructs (namely, of MV2) has an estimated affinity of $\sim 0.5 \mu M$, suggesting additional interaction surfaces between the two proteins. Work is in progress to investigate the kinetic and thermodynamic details of the binding process between DLC2 and myoVa.

In regard to the function of DLCs as subunits of motor proteins, previous suggestions were stabilizing, cargo binding, and/or some regulatory roles (7, 34). Our results are consistent with a role as a molecular glue (see above). When exon B and its associated DLC2 were brought in close proximity to the two heavy chains and hence stabilized the medial and proximal coiled-coil domains, they could form or expose binding sites for additional regulatory proteins/cargos and/or could provide the globular tail domain with extra cargo-interacting specificity as suggested for the other two alternative tail exons (16). If exon B and DLC2 have this property, then myoVa isoforms with and without exon B could have specific roles. The stability of the medial coiled-coil domain indeed seems to be critical to the myoVa function; the mutation of Leu1211 to a Gln (a core d position in the medial coiled-coil domain) was found in a dilute mutant mouse (11). Another possible role of DLC2 could be its involvement in the regulation of the motor activity. The current model of regulation suggests that full-length myoVa in the presence of low Ca$^{2+}$ can adopt an inhibited compact conformation, where the globular tail domains are folded back to the two heads. Cargo binding or elevated Ca$^{2+}$ would unlock the motor by independent pathways (17–20). The tail light chain, bound to the flexible exon B containing the domain between the medial and distal coiled-coils, would be in an ideal position to affect the inhibitory folded state. On early electron microscopy (EM) pictures of brain-isolated myoVa, Cheney et al. (8) observed molecules with the globular tail domain superimposed on a tail region that could easily be DBD with bound DLC2. If such an interaction exists, it could provide an additional level of regulation in class V myosins.

Finally, the key question remains whether DLC2 (or DLC1 on the dynein motor) could act as a cargo-binding adaptor protein or not? In this respect, the symmetric nature of the partner binding groove of DLC raises some concern if the myoVa heavy chains and the dynein intermediate chains occupy both binding grooves of DLC. As a consequence, one of the motor chains must be displaced by the cargo for the cargo to bind. This so-called cargo-binding problem could be solved if the binding sites are asymmetric and/or binding to the dimeric motor displaces negative cooperativity. A similar situation exists in Tctex1, another DLC (72, 73). For this structural homologue of DLC, the binding site to the dynein intermediate chain is distinct from the potential cargo binding site (74), allowing for the binding of rhodopsin cargo without disrupting the Tctex1–motor interaction. In the case of the DLC2–myoVa complex, our results suggest that the DLC dimer brings together the two heavy chains by binding simultaneously to them. These results are more consistent with a symmetric binding model; however, we cannot rule out that the two interfaces between the DLC dimer and the exon B containing heavy chains are not fully identical and somehow allow for the simultaneous binding of DLC2 to the heavy chain and the cargo protein. Further structural and kinetic studies are required to understand the detailed mechanism of cargo binding to the assembled myoVa motor complex.

ACKNOWLEDGMENT

We are grateful to Katalin Kurucz-Váradi for her excellent technical assistance, Erika Kovács for making the constructs for the transfection experiments, Dr. András Patthy for peptide synthesis and sequencing, and Dr. Péter Závodszky for allowing us to use his spectropolarimeter. We thank Dr. M. G. Hinds for providing his sequence assignment of the HSQC spectra of DLC2 and Dr. Rodriguez-Crespo for providing the DLC-binding nNOS peptide. We also thank L. Farkas, J. Kardos, M. Kovács, and J. Tóth for their helpful discussions and comments.

REFERENCES

Biochemistry, Vol. 45, No. 41, 2006


